31162-13-7

Usage

Synthesis

The solution of the corresponding 2-aminobenzoic acid (15.3 mmol) in water (15 mL) and conc. HCl (17 mL) was placed in a 200 mL beaker and cooled to 5 °C. To this mixture a precooled solution of sodium nitrite (1.06 g, 15.3 mmol in 10 mL water) was added drop wise with vigorous stirring. After stirring for 15 min, a solution of sodium azide (1.08 g, 16.6 mmol) in 10 mL water was added and the resulting mixture was gradually warmed to room temperature and stirred at this temperature for about 2 h. The white crystalline azides precipitated from the reaction mixture and were filtered off. After washing with cold water and drying in the dark at room temperature the azides were recrystallized from heptane/benzene (v/v, 1:1).?1H NMR (400 MHz, CDCl3) δ 10.65 ?(s, 1H), 8.11 (dd, J = 7.9, 1.5 Hz, 1H), 7.66 – 7.56 (m, 1H), 7.31 – 7.21 (m, 2H). 13C ?NMR (101 MHz, CDCl3) δ 168.8, 140.4, 134.6, 133.4, 125.1, 120.9, 119.7.

Uses

2-Azidobenzoic Acid can be used for polyethylene surface with aryl azides.

Upstream product

• 16714-25-3 2-azidobenzaldehyde 
• 31656-77-6 2-azidobenzonitrile 
• 612-27-1 2-nitroso-benzoic acid 
• 40515-78-4 (E)-3-(2-azidophenyl)acrylic acid 
• 118-92-3 anthranilic acid 
• 41225-81-4 3-amino-1,2,3-benzotriazin-4(3H)-one 
• 88-67-5 2-Iodobenzoic acid 
• 34897-85-3 o-azidobenzoyl chloride 
• 552-89-6 2-nitro-benzaldehyde 
• 1427465-29-9 1-(4-methylphenyl)-1H-1λ³-benzo[b]iodo-3(2H)-one 
• 1427465-34-6 1-(2,4,6-trimethylphenyl)-1H-1λ³-benzo[b]iodo-3(2H)-one 
• 1427465-36-8 1-(4-chlorophenyl)-1λ³-benzo[d][1,2]iodaoxol-3(1H)-one 
• 552-16-9 ortho-nitrobenzoic acid 
• 90701-81-8 2-azidobenzohydrazide 

Downstream Products

• 118-92-3 anthranilic acid 
• 573-79-5 2,2'-azoxy-di-benzoic acid 
• 70036-30-5 N-triphenylphosphoranyliden-anthranilic acid 
• 31120-32-8 2-(Diethoxy-phosphorylamino)-benzoic acid ethyl ester 
• 2183-86-0 1,3-dihydro-2H-azepin-2-one 
• 134050-77-4 3H-azepin-2-one-3-carboxylic acid 
• 117663-72-6 6H-azepino<2,1-b>quinazolin-12-one 
• 34897-85-3 o-azidobenzoyl chloride 
• 635-54-1 2,2'-azobenzoic acid 
• 90408-03-0 4-methylbenzyl 2-azidobenzoate 
• 29951-97-1 2-(2-azidophenyl)benzimidazole 
• 160060-61-7 2-Azido-N-(2-azido-phenyl)-benzamide 
• 160060-83-3 2-azido-N-(2-azidobenzyl)benzamide 
• 160060-84-4 2-azido-N-<(2-azidophenyl)ethyl>benzamide 

Relevant academic research and scientific papers

One-pot synthesis of triazoloquinazolinones via copper- catalyzed tandem click and intramolecular C-H amidation

A novel and highly efficient copper-catalyzed tandem synthesis of triazoloquinazolinones is explored. The synthetic strategy involves a sequential one-pot click reaction followed by aerobic intramolecular C-H amidation. Two distinct and important transfor

Synthesis, antiproliferative, docking and DFT studies of benzimidazole derivatives as EGFR inhibitors

In the present work, new benzimidazole linked 1,2,3-triazole hybrids have been synthesized and screened for antiproliferative and EGFR kinase inhibitory activities.The structures of these hybrids were elucidated using IR, NMR, mass spectrometry and elemen

Benzimidazole–galactosides bind selectively to the Galectin-8 N-Terminal domain: Structure-based design and optimisation

We have obtained the X-ray crystal structure of the galectin-8 N-terminal domain (galectin-8N) with a previously reported quinoline–galactoside ligand at a resolution of 1.6 ?. Based on this X-ray structure, a collection of galactosides derivatised at O3 with triazole, benzimidazole, benzothiazole, and benzoxazole moieties were designed and synthesised. This led to the discovery of a 3-O-(N-methylbenzimidazolylmethyl)–galactoside with a Kd of 1.8 μM for galectin-8N, the most potent selective synthetic galectin-8N ligand to date. Molecular dynamics simulations showed that benzimidazole–galactoside derivatives bind the non-conserved amino acid Gln47, accounting for the higher selectivity for galectin-8N. Galectin-8 is a carbohydrate-binding protein that plays a key role in pathological lymphangiogenesis, modulation of the immune system, and autophagy. Thus, the benzimidazole-derivatised galactosides represent promising compounds for studies of the pathological implications of galectin-8, as well as a starting point for the development of anti-tumour and anti-inflammatory therapeutics targeting galectin-8.

One-Step Synthesis of 2-[(2-Carboxyphenyl)amino]-6-formylnicotinic Acid via Photolysis of 2-Azidobenzoic Acid in the Presence of Weak Bases

Abstract: 2-Azidobenzoic acid has undergone rearrangement into 2-[(2-carboxyphenyl)amino]-6-formylnicotinic acid under irradiation in aqueous-organic media in the presence of acetates of alkali or alkaline earth metals. The structure of the resulting comp

Design, synthesis, and evaluation of new 4(3H)-quinazolinone derivatives containing a pyrazole carboxamide moiety

A total of 15 new 4(3H)-quinazolinone derivatives containing a pyrazole carboxamide moiety were designed and synthesized in this study. The structures of the target compounds were elucidated using 1H NMR, 13C NMR, MS, and elemental a

Catalyst-Controlled Regioselective Synthesis of Benzotriazlolodiazepin-7-ones and Benzotriazolodiazocin-8-ones

A catalyst-controlled highly chemoselective and regioselective intramolecular cycloamidation of triazol-1-ylbenzamides toward the synthesis of scarcely known heterocycles is reported. In the presence of a palladium catalyst, this cycloisomerization reacti

Novel fused 1,2,3-triazolo-benzodiazepine derivatives as potent anticonvulsant agents: design, synthesis, in vivo, and in silico evaluations

Abstract: A novel series of 1,2,3-triazolo-benzodiazepine derivatives 6a–o has been synthesized and evaluated in vivo for their anticonvulsant activities using by pentylenetetrazole (PTZ)- and maximal electroshock (MES)-induced seizures in mice. The synth

Telescoped synthesis of C3-functionalized (E)-arylamidines using Ugi-Mumm and regiospecific quinazolinone rearrangements

An efficient four-step, six-transformation protocol was developed to afford bioactive N-alkyl- or N-arylamide (E)-arylamidines featuring strategic amidine C3 modifications which were inaccessible or low yielding by previous methods. This synthetic approac

Fragment-Based Discovery of a Qualified Hit Targeting the Latency-Associated Nuclear Antigen of the Oncogenic Kaposi's Sarcoma-Associated Herpesvirus/Human Herpesvirus 8

The latency-associated nuclear antigen (LANA) is required for latent replication and persistence of Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8. It acts via replicating and tethering the virus episome to the host chromatin and exerts other functions. We conceived a new approach for the discovery of antiviral drugs to inhibit the interaction between LANA and the viral genome. We applied a biophysical screening cascade and identified the first LANA binders from small, structurally diverse compound libraries. Starting from a fragment-sized scaffold, we generated optimized hits via fragment growing using a dedicated fluorescence-polarization-based assay as the structure-activity-relationship driver. We improved compound potency to the double-digit micromolar range. Importantly, we qualified the resulting hit through orthogonal methods employing EMSA, STD-NMR, and MST methodologies. This optimized hit provides an ideal starting point for subsequent hit-to-lead campaigns providing evident target-binding, suitable ligand efficiencies, and favorable physicochemical properties.

Fragment-Based Discovery of a Qualified Hit Targeting the Latency-Associated Nuclear Antigen of the Oncogenic Kaposi's Sarcoma-Associated Herpesvirus/Human Herpesvirus 8

The latency-associated nuclear antigen (LANA) is required for latent replication and persistence of Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8. It acts via replicating and tethering the virus episome to the host chromatin and exerts other functions. We conceived a new approach for the discovery of antiviral drugs to inhibit the interaction between LANA and the viral genome. We applied a biophysical screening cascade and identified the first LANA binders from small, structurally diverse compound libraries. Starting from a fragment-sized scaffold, we generated optimized hits via fragment growing using a dedicated fluorescence-polarization-based assay as the structure-activity-relationship driver. We improved compound potency to the double-digit micromolar range. Importantly, we qualified the resulting hit through orthogonal methods employing EMSA, STD-NMR, and MST methodologies. This optimized hit provides an ideal starting point for subsequent hit-to-lead campaigns providing evident target-binding, suitable ligand efficiencies, and favorable physicochemical properties.